(NASDAQ: CTMX) Cytomx Therapeutics's forecast annual revenue growth rate of -10.89% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.57%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.16%.
Cytomx Therapeutics's revenue in 2024 is $101,214,000.On average, 5 Wall Street analysts forecast CTMX's revenue for 2024 to be $5,764,264,364, with the lowest CTMX revenue forecast at $3,386,082,900, and the highest CTMX revenue forecast at $7,313,939,064. On average, 5 Wall Street analysts forecast CTMX's revenue for 2025 to be $5,443,466,870, with the lowest CTMX revenue forecast at $3,386,082,900, and the highest CTMX revenue forecast at $7,313,939,064.
In 2026, CTMX is forecast to generate $4,713,427,397 in revenue, with the lowest revenue forecast at $3,386,082,900 and the highest revenue forecast at $6,040,771,894.